Valeant Pharmaceuticals has signed a definitive agreement to acquire Coria Laboratories, Ltd., a specialty pharmaceutical company focused on dermatology products in the U.S., for $95 million. This acquisition expands Valeant’s U.S. business and adds to its dermatology franchise with the acquisition of several products, for which annual sales are approximately $40 million. Coria was owned by DFB Laboratories, which also owns DPT Laboratories, a contract development and manufacturing organization ...